Rethinking Diabetes Care: PatentVest Pulse Unveils Key Insights on the Expanding CGM Market and the Innovations Driving Change

Rhea-AI Summary

PatentVest has released a comprehensive report on the Continuous Glucose Monitoring (CGM) market, highlighting significant growth prospects and technological innovations in diabetes care. The report reveals that the global CGM market, valued at $11.63 billion in 2024, is projected to reach $21 billion by 2029.

The analysis addresses the critical need for continuous glucose monitoring solutions, noting that diabetes affects 537 million adults worldwide, with projections reaching 783 million by 2045. Key market drivers include technological advancements in non-invasive monitoring, integration with mobile applications, and the emergence of over-the-counter (OTC) CGM products.

The report emphasizes the competitive landscape dominated by major players like Dexcom, Abbott, Medtronic, and Roche, highlighting their role in transforming diabetes management through innovation and strategic market positioning. A surge in patent filings and ongoing litigation trends underscore the market's competitive nature.

Positive

• CGM market projected to grow from $11.63B (2024) to $21B (2029)
• Large addressable market with 537M diabetic adults worldwide, expected to reach 783M by 2045
• Expanding market opportunities through OTC products and non-invasive monitoring solutions

Negative

• None.

Addison, TX, Jan. 07, 2025 (GLOBE NEWSWIRE) -- PatentVest, a leader in intellectual property (IP) intelligence and strategy, has released its latest report, “Continuous Glucose Monitoring (CGM): An Evolving Innovation Landscape.” This in-depth analysis explores the rapidly growing CGM market, offering valuable insights into the trends, key players, and opportunities that are shaping the future of diabetes care.

Diabetes is one of the most pressing global health challenges, affecting an estimated 537 million adults worldwide in 2021—a number projected to rise to 783 million by 2045. As the complexity of diabetes management grows, the need for continuous, real-time glucose monitoring has never been more critical. Continuous Glucose Monitors (CGMs) address these challenges by providing patients with timely insights into their glucose levels, enabling more informed decision-making and better health outcomes.

Valued at $11.63 billion in 2024, the CGM market is projected to reach $21 billion by 2029, driven by technological advancements, greater accessibility, and the growing availability of non-invasive, over-the-counter (OTC) solutions.

Key Factors Shaping the Market:

• Technological Advancements: Innovations in CGM technology, including non-invasive glucose monitoring and seamless integration with mobile applications, are improving the convenience, accuracy, and accessibility of diabetes care.

• Market Dynamics: The emergence of OTC CGM products is broadening access to diabetes care, particularly for non-insulin-dependent patients and wellness-focused individuals, creating a significant shift in the market.

• Intellectual Property Strategy: The CGM market is characterized by a surge in patent filings, as companies race to protect their innovations and secure leadership positions. Ongoing litigation trends further highlight the high stakes in this rapidly evolving market.

“While there is currently no simple cure for diabetes, this report provides key insights into how major players like Dexcom, Abbott, Medtronic, and Roche are advancing innovative solutions to transform diabetes management,” said Will Rosellini, Chief IP Officer at PatentVest. “Through technological advancements, strategic market moves, and evolving IP strategies, these companies are shaping the future of diabetes care and expanding access to critical monitoring tools.”

PatentVest’s report provides in-depth analysis of these factors and offers actionable insights for companies, investors, and healthcare leaders navigating the CGM space.

Access the Full Report
The PatentVest Pulse report is now available. Gain comprehensive insights into the trends, technologies, and competitive dynamics driving the CGM market: Access the full report here.

For more information or inquiries, please contact info@patentvest.com.

About PatentVest
PatentVest, a division of MDB Capital Holdings (Nasdaq: MDBH), is the first integrated IP intelligence, strategy, and law firm to enable visionary companies to develop into technology leaders. By combining our proprietary database with a time proven IP diligence process and expert analysis, we deliver actionable insights on the IP landscape to help our clients make informed decisions and stay ahead of the curve. The trends and competitive insights in this report are powered by PatentVest's proprietary IP intelligence platform. Our reports keep a pulse on the key players, technologies, and opportunities shaping deep technology markets.

FAQ

What is the projected market value for CGM technology by 2029?

According to PatentVest's report, the CGM market is projected to reach $21 billion by 2029, growing from $11.63 billion in 2024.

How many people globally are affected by diabetes in 2021?

The report indicates that diabetes affected an estimated 537 million adults worldwide in 2021, with projections showing an increase to 783 million by 2045.

What are the key factors driving growth in the CGM market?

The key factors include technological advancements in non-invasive monitoring, integration with mobile applications, and the emergence of over-the-counter (OTC) CGM products.

Who are the major players in the CGM market according to PatentVest?

The report identifies Dexcom, Abbott, Medtronic, and Roche as major players in the CGM market.

What is the current market value of the CGM industry in 2024?

The CGM market is valued at $11.63 billion in 2024 according to PatentVest's report.